Amundi’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$405M Buy
6,673,998
+642,539
+11% +$37.5M 0.11% 164
2025
Q4
$325M Buy
6,031,459
+57,037
+1% +$2.74M 0.09% 228
2025
Q3
$270M Buy
5,974,422
+194,283
+3% +$9.07M 0.09% 209
2025
Q2
$275M Buy
5,780,139
+513,255
+10% +$25.2M 0.1% 202
2025
Q1
$305M Buy
5,266,884
+127,236
+2% +$7.42M 0.11% 189
2024
Q4
$292M Sell
5,139,648
-2,655,099
-34% -$148M 0.1% 193
2024
Q3
$409M Sell
7,794,747
-576,788
-7% -$27.1M 0.15% 142
2024
Q2
$335M Buy
8,371,535
+2,503,473
+43% +$112M 0.13% 154
2024
Q1
$288M Buy
5,868,062
+876,155
+18% +$44.6M 0.12% 178
2023
Q4
$256M Sell
4,991,907
-1,084,804
-18% -$56.9M 0.12% 202
2023
Q3
$343M Sell
6,076,711
-93,540
-2% -$5.73M 0.17% 136
2023
Q2
$398M Sell
6,170,251
-1,596,638
-21% -$107M 0.2% 119
2023
Q1
$542M Sell
7,766,889
-684,476
-8% -$48.3M 0.29% 81
2022
Q4
$608M Buy
8,451,365
+1,173,021
+16% +$88.4M 0.33% 72
2022
Q3
$520M Buy
7,278,344
+1,914,982
+36% +$139M 0.31% 72
2022
Q2
$398M Buy
5,363,362
+1,195,638
+29% +$91.1M 0.32% 77
2022
Q1
$321M Buy
4,167,724
+743,321
+22% +$49.9M 0.22% 117
2021
Q4
$221M Sell
3,424,403
-1,927,571
-36% -$113M 0.14% 173
2021
Q3
$317M Buy
5,351,974
+48,819
+0.9% +$3.22M 0.22% 109
2021
Q2
$354M Buy
+5,303,155
New +$346M 0.25% 92

Other funds holding BMY

Amundi's BMY Position: Q1 2026 in Review

Amundi increased its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2026, buying an estimated $37.5M and bringing the position to 6,673,998 shares worth $405M. The position accounts for 0.11% of the portfolio, ranked #164.

Amundi first reported a position in BMY in Q2 2021 and has held it in 20 quarters since. The position peaked at $608M in Q4 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Amundi held 6,673,998 shares of Bristol-Myers Squibb worth $405M as of Q1 2026.
  • Amundi bought 642,539 Bristol-Myers Squibb shares in Q1 2026, an estimated $37.5M.
  • Bristol-Myers Squibb made up 0.11% of Amundi's portfolio in Q1 2026, its #164 holding.
  • Amundi first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 20 quarters since.
  • Amundi's Bristol-Myers Squibb position peaked at $608M in Q4 2022.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.